Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Cetuximab Beta + mFOLFOX6 in mCRC
NCT06959693Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Sep 2028
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of envafolimab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06959693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959693.